Navigation Links Website Offers Latest on Assessing Prostate Cancer Risk
Date:9/14/2010 Website Offers Latest on Assessing Prostate Cancer Risk -- NYON, Switzerland, September 15, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Web Site, Publishing & Information Services, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, New Products & Services Click to view news release full screen Website Offers Latest on Assessing Prostate Cancer Risk


NYON, Switzerland, September 15, 2010 /PRNewswire/ --

- Site Provides Information on New Blood Test and Unique Index to Help Reduce Unnecessary Biopsies - a major online resource to help assess risk for prostate cancer - is now available in five languages, English, French German, Italian and Spanish.

Created by the scientific team behind the world's largest independent medical diagnostics company - Beckman Coulter, Inc. (European headquarters in Nyon, Switzerland) - provides educational information for patients, physicians and clinical laboratory staff.

The newly launched site describes the medical research behind a new blood test (p2PSA), and the Prostate Health Index (phi), that scientists have created to significantly improve a patient's risk assessment for prostate cancer.

"The dilemma faced by men with an elevated prostate-specific antigen, or PSA test, is how to find out if they actually have prostate cancer," explained Peter Heseltine, M.D, medical director for Beckman Coulter. "That usually meant undergoing an invasive prostate biopsy. The search has been underway for several years to find a non-invasive way of assessing cancer risk."

And Dr. Heseltine added: "The Prostate Health Index (phi) provides clinicians with a way of combining and interpreting three blood tests that measure different forms of the PSA protein. The index is a risk assessment tool for prostate cancer. A low phi result indicates a lower risk of prostate cancer, while an elevated phi suggests that it may be appropriate to have a prostate biopsy."

The new website encourages dialogue between patients, physicians and laboratory professionals, and provides guidance and education, fostering more informed prostate biopsy decision-making. Included are links to medical resources and the latest scientific studies.

As one example, recent findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) showed a 30 percent mortality reduction from prostate cancer deaths if PSA levels were monitored over approximately seven years. So, while the current PSA test informs doctors there may be a problem with the prostate, it does not indicate what the specific problem is - cancer or no cancer.

Notes to Editor

Patient Leaflet

To obtain a free digital copy of the leaflet Do I need a prostate biopsy? simply send your e-mail address by filling out the form at

Research findings

These include a recent study published in The Journal of Urology, which confirmed that the phi score is a better predictor of prostate cancer risk than PSA or percent free PSA alone in men 50 years of age and older with a PSA range of 2-10 ng/mL who had a digital rectal exam with no suspicious findings.[1]


[1] Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, Catalona WJ. [-2] pro-PSA is more accurate than total and free PSA in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J of Urology 2010 April; 183(4):1355-1359.

The Beckman Coulter phi

This combines three automated blood tests into one index that estimates a man's probability of having prostate cancer found on biopsy. Beckman Coulter phi is a composite score of Access Hybritech PSA, free PSA and the new p2PSA (not available in the United States) assay, which measures the free PSA isoform [-2]proPSA. This assessment can only be carried out in a hospital or medically approved laboratory.

About Beckman Coulter

Beckman Coulter, Inc., a $3.3 billion company based in California, USA, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. For more information, visit

SOURCE Beckman Coulter Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Millstone Medical Outsourcing Launches New, Improved Company Website
2. Medical Website Design Experts Aurora Information Technology Introduces Its Newest Website Launch, Muscat Eye Laser Center
3. Dynatronics Launches E-Commerce Website
4. China Medical Technologies Announces the Recent Publication of a Study on its SPR Analyzer and HPV DNA Chip in Cancer Genetics and Cytogenetics and the Creation of a Medical Publications Column to the Investor Relations Section on its Website
5. United Seating & Mobility Launches New Company Website and E-Commerce Store at
6. New Corporate Profile Posted On CardioGenics Website
7. Best Health Care Website of 2010 to be Named by Web Marketing Association in 14th Annual WebAward Competition
8. Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
9. Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New Website
10. Vivakor Announces Launch of VivaThermic Website and Highlights Distribution & Sales of Its VivaThermic Products in Japan Through Veritas Corporation
11. Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
Breaking Medicine Technology:
(Date:11/27/2015)... Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... for use in Final Cut Pro X. With ProSidebar: Fasion, video editors can ... or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating drop ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A simply groundbreaking ... is an interesting show that delves into an array of issues that are presently ... could benefit from open dialogue, this show is changing the subjects consumers focus on, ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point Recovery, ... together on Thanksgiving Day to share the things that they are most grateful ... Point YouTube channel, patients displayed what they wrote on index cards, describing the ...
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
Breaking Medicine News(10 mins):